GSK's Jemperli follows Merck's Keytruda with FDA nod to target certain tumors regardless of location

GlaxoSmithKline’s PD-1 latecomer Jemperli has scored an FDA go-ahead to expand into a larger cancer field. Once again, it’s following in the footsteps of Merck’s market leader Keytruda, but first-in-class opportunities await down the line.